Scand J Rheumatol 2018;47:465-474. doi: 10.1080/03009742.2018.1444199.
B Glintborg, U Lindström, K Aaltonen, EK Kristianslund, B Gudbjornsson, K Chatzidionysiou, J Askling, D Nordström, ML Hetland, D Di Giuseppe, L Dreyer, LE Kristensen, TS Jørgensen, K Eklund, G Grondal, S Ernestam, J Joensuu, MRK Törmänen, H Skydsgaard, J Hagfors, TK Kvien, E Lie, K Fagerli, AJ Geirsson, H Jonsson, SA Provan, NS Krogh and LTH Jacobsson. On behalf of: the DANBIO Registry, Copenhagen, Denmark; the SRQ/ARTIS Registry, Stockholm, Sweden; the ROB-FIN Registry, Helsinki, Finland; the NOR-DMARD Registry, Oslo, Norway; the ICEBIO Registry, Reykjavik, Iceland. Biological treatment in ankylosing spondylitis in the Nordic countries during 2010–2016: a collaboration between five biological registries.
When the original article was published the financial support for the study was not fully acknowledged. The Acknowledgements should have included that the study was partly funded by NordForsk and FOREUM.
The authors apologise for this error.
The correct Acknowledgements follows.
Thanks to the patient partners HS, JH, and MT, who contributed on behalf of the DANBIO Registry, Copenhagen, Denmark, the SRQ/ARTIS Registry, Stockholm, Sweden, the ROB-FIN Registry, Helsinki, Finland, the NOR-DMARD Registry, Oslo, Norway, and the ICEBIO Registry, Reykjavik, Iceland.
The study was partly funded by NordForsk and FOREUM.